Abstract
Uterine cervical cancer (UCC) remains a major cause of cancer-related mortality among women. This study investigates the patterns of distant metastases and prognostic factors in patients with FIGO stage IVB UCC. Using data from the Surveillance, Epidemiology, and End Results (SEER) database (n=1,448) and a validation cohort from Tianjin First Central Hospital (n=227), researchers analyzed survival outcomes based on the number and location of metastatic sites. Results showed that 30.8% of patients had multiple metastatic sites, which correlated with significantly worse survival (5 months) compared to single-site metastasis (8 months). Key prognostic factors included age, race, tumor grade, and the number of metastatic sites.
Introduction: The Challenge of Advanced UCC
While early detection has improved outcomes for many, approximately 13% of uterine cervical cancer (UCC) cases are diagnosed at FIGO Stage IVB, where the disease has spread to distant organs. Historically, research on advanced UCC has been limited by small cohorts or a narrow focus on specific metastatic sites. This population-based study provides a comprehensive analysis of how different metastatic patterns—specifically the number and combination of involved organs—impact patient prognosis.
Methods and Study Design
The researchers utilized a retrospective cohort design across two distinct populations:
- Study Group: 1,448 patients from the SEER database (2010–2016), representing a broad US population.
- Validation Group: 227 patients from Tianjin First Central Hospital (2004–2017) to ensure the findings' generalizability.
The study focused on four primary metastatic sites: bone, brain, liver, and lung. Survival was estimated using Kaplan-Meier analysis, and independent prognostic factors were identified via Cox proportional hazard regression.
Key Insights: Patterns of Spread and Survival
The study revealed a clear correlation between the extent of metastatic spread and patient survival. Approximately 70% of patients presented with a single metastatic site, with the lung being the most frequent destination (65.0% of the total group).
A significant "survival gap" was observed:
- Single-site metastasis: Median overall survival (OS) of 8 months.
- Multiple-site metastasis: Median OS of 5 months.
The risk of death increased by approximately 65-68% for patients with two or more metastatic sites compared to those with only one. Furthermore, the specific combination of sites mattered; for instance, patients with brain involvement generally faced a poorer prognosis than those with isolated bone metastases.
Prognostic Factors
Multivariate analysis identified several independent risk factors for poor prognosis across the entire cohort:
- Demographics: Age ≥ 65 years and Black race.
- Clinical Characteristics: Higher tumor grade and higher T-stage (primary tumor size/extent).
- Metastatic Burden: Presence of two or more metastatic sites.
Interestingly, the relevance of these factors shifted depending on the metastatic pattern. For patients with two metastatic sites, insurance status and surgical history emerged as significant predictors, whereas race and T-stage were more dominant in single-site cases.
Limitations and Future Directions
The study's reliance on the SEER database introduces certain limitations, such as the lack of detailed data on distant lymph node involvement, peritoneal spread, and specific treatment regimens like chemotherapy or radiotherapy. Additionally, biological markers such as HPV status were not included. Future research integrating genomic data and more granular treatment records is necessary to further refine these prognostic models and guide personalized treatment strategies for advanced UCC.
Summary updated